myeloid

(redirected from myelogenous)
Also found in: Dictionary, Medical.

myeloid

[′mī·ə‚lȯid]
(anatomy)
Of or pertaining to bone marrow.
Of or pertaining to the spinal cord.
References in periodicals archive ?
The Type II Variation application for BOSULIF for adults with newly diagnosed chronic phase Ph+ CML was based on results from BFORE (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment), a randomized multicenter, multinational, open-label, Phase 3, head-to-head study of BOSULIF 400 mg versus imatinib 400 mg, a current standard of care.
About 90 percent of chronic myelogenous leukemia patients treated with imatinib survive for 5 years or longer.
The IOM's subsequent review of the evidence found there is "inadequate or insufficient evidence" to establish a connection between the parent's Agent Orange exposure and development of acute myelogenous leukemia.
The incidence rate of acute myelogenous leukemias (AMLs) in the United States is approximately 2.
com/research/e2e018/chronic_myelogenou) has announced the addition of GlobalData's new report "Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.
M2 PHARMA-May 19, 2015-Agios passes US FDA's fast track designation for AG-120 for treating acute myelogenous leukemia
M2 EQUITYBITES-May 19, 2015-Agios passes US FDA's fast track designation for AG-120 for treating acute myelogenous leukemia
William ``Pete'' Knight, R-Palmdale, is hospitalized with acute myelogenous leukemia and will be undergoing treatment, a spokesman said Tuesday.
The medicine known commercially as Gleevec serves as a powerful weapon for people fighting the blood cancer called chronic myelogenous leukemia, or CML.
com/research/f4ffea/acute_lymphoblasti) has announced the addition of the "Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report" report to their offering.
M2 EQUITYBITES-December 9, 2014-AbbVie reveals results from Phase 2 study of venetoclax in patients with acute myelogenous leukaemia
M2 PHARMA-December 9, 2014-AbbVie reveals results from Phase 2 study of venetoclax in patients with acute myelogenous leukaemia